David Bredt's most recent trade in Rapport Therapeutics Inc. was a trade of 8,300 Common Stock done at an average price of $15.0 . Disclosure was reported to the exchange on Aug. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.98 per share. | 15 Aug 2025 | 8,300 | 426,842 | - | 15.0 | 124,308 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.79 per share. | 15 Aug 2025 | 200 | 426,642 | - | 15.8 | 3,158 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 15 Jul 2025 | 8,500 | 435,142 | - | 14.0 | 118,962 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 16 Jun 2025 | 8,500 | 443,642 | - | 11.0 | 93,522 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.56 per share. | 15 May 2025 | 8,500 | 452,142 | - | 9.6 | 81,262 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 15 Apr 2025 | 8,500 | 460,642 | - | 9.6 | 81,310 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 14 Mar 2025 | 8,500 | 469,142 | - | 10.8 | 92,205 | Common Stock |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc. | David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 28,302 | 28,302 | - | - | Stock Option (Right to Buy) |